International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) Voir le document au format PDF
Table des matières
Afficher le documentAbstract
Afficher le documentAcknowledgments
Afficher le documentInformation on authors
Afficher le documentExchange rates used in the report
Ouvrir ce répertoire et afficher son contenuChapter 1: Policies for praziquantel*
Ouvrir ce répertoire et afficher son contenuChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Ouvrir ce répertoire et afficher son contenuChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Ouvrir ce répertoire et afficher son contenuChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Ouvrir ce répertoire et afficher son contenuChapter 5: The international supply of praziquantel*
Ouvrir ce répertoire et afficher son contenuChapter 6: Demand for praziquantel and national distribution*
Fermer ce répertoireChapter 7: Prices and production costs of praziquantel*
Afficher le documentThe price of praziquantel
Afficher le documentProduction costs and pricing strategies of major producers
Afficher le documentReferences
Afficher le documentOther documents in the DAP Research Series
Afficher le documentDAP Research Series No. 26
 

Chapter 7: Prices and production costs of praziquantel*

* By Ramesh Govindaraj, Michael R. Reich, and Karin Dumbaugh.

This chapter examines the prices of praziquantel in various market segments, and the production costs of praziquantel. The section on pricing traces changes in praziquantel prices over time, and presents data on: current prices at which praziquantel is purchased by bulk suppliers; prices obtained by developing countries through tenders; and prices at which the drug is sold by producers in the private market in developed and developing countries. The section on production costs discusses the costs of manufacturing praziquantel faced by the major producers, and their pricing strategies. The section also explores problems experienced by Bayer and E. Merck in competing in the international market with lower-priced producers, who have successfully used process patent laws to develop alternative (and much cheaper) processes for producing praziquantel.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013